TG Therapeutics (NASDAQ: TGTX) issues 2025 revenue update, 2026 outlook

Rhea-AI Filing Summary

TG Therapeutics, Inc. filed a current report to share that it has released a press release providing preliminary fourth quarter and full year 2025 net product revenue, along with 2026 revenue guidance and anticipated development milestones.

The company furnished this information under a Regulation FD disclosure, attaching the full press release as Exhibit 99.1. The exhibit contains the detailed financial figures and milestone timelines, while the report itself mainly documents that this information has been made publicly available.

false 0001001316 0001001316 2026-01-13 2026-01-13

 ​​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 13, 2026

TG Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-32639	36-3898269
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer Identification No.)
of Incorporation)	​	​

 ​

3020 Carrington Mill Blvd, Suite 475

Morrisville, North Carolina 27560

(Address of Principal Executive Offices)

(212) 554-4484

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities filed pursuant to Section 12(b) of the Act:

Title of Class	Trading Symbol(s)	Exchange Name
Common Stock	TGTX	Nasdaq Capital Market

 ​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure

On January 13, 2026, the Company issued a press release entitled “TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones.”

For purposes of this Item 7.01, the Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press release issued by TG Therapeutics, Inc., dated January 13, 2026.
​	​	​
Exhibit 104		The cover page from this Current Report on Form 8-K formatted in Inline XBRL.

 ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	TG Therapeutics, Inc.
​	(Registrant)
Date: January 13, 2026	By:	/s/ Sean A. Power
​	​	Sean A. Power
​	​	Chief Financial Officer

 ​

 ​

FAQ

What did TG Therapeutics (TGTX) disclose in this 8-K filing?

TG Therapeutics disclosed that it issued a press release providing preliminary fourth quarter and full year 2025 net product revenue, as well as 2026 revenue guidance and anticipated development milestones, which is attached as Exhibit 99.1.

Which financial information does TG Therapeutics provide in the attached press release?

The attached press release includes preliminary net product revenue for Q4 2025 and full year 2025, along with revenue guidance for 2026.

Does the TG Therapeutics 8-K include detailed numbers for 2025 revenue and 2026 guidance?

The 8-K itself summarizes the disclosure and notes that detailed figures for preliminary 2025 net product revenue and 2026 revenue guidance are contained in the press release attached as Exhibit 99.1.

How is the TG Therapeutics press release treated for SEC purposes in this report?

The press release furnished as Exhibit 99.1 is provided under Item 7.01 Regulation FD Disclosure and is expressly stated as being furnished, not filed, which affects how it is treated under certain liability provisions of the Exchange Act.

What exhibit is included with the TG Therapeutics 8-K filed on January 13, 2026?

The filing includes Exhibit 99.1, which is the press release titled “TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones,” dated January 13, 2026.

Who signed the TG Therapeutics 8-K related to the 2025 revenue update?

The report was signed on behalf of TG Therapeutics, Inc. by Sean A. Power, who is identified as the company’s Chief Financial Officer.